Home › Compare › CDXI vs NOBL

CDXI vs NOBL: Dividend Comparison 2026

CDXI yields 2000000.00% · NOBL yields 4.00%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CDXI wins by $4.879226400974806e+39M in total portfolio value
10 years
CDXI
CDXI
● Live price
2000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.879226400974806e+39M
Annual income
$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00
Full CDXI calculator →
NOBL
NOBL
● Live price
4.00%
Share price
$50.00
Annual div
$2.00
5Y div CAGR
5%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$28.0K
Annual income
$899.19
Full NOBL calculator →

Portfolio growth — CDXI vs NOBL

📍 CDXI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCDXINOBL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CDXI + NOBL cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
CDXI pays
NOBL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CDXI
Annual income on $10K today (after 15% tax)
$170,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/yr
NOBL
Annual income on $10K today (after 15% tax)
$340.00/yr
After 10yr DRIP, annual income (after tax)
$764.31/yr
At 15% tax rate, CDXI beats the other by $4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CDXI + NOBL for your $10,000?

CDXI: 50%NOBL: 50%
100% NOBL50/50100% CDXI
Portfolio after 10yr
$2.439613200487403e+39M
Annual income
$2,439,373,269,665,485,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.99%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CDXI buys
0
NOBL buys
0
No recent congressional trades found for CDXI or NOBL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCDXINOBL
Forward yield2000000.00% ✓4.00%
Annual dividend / share$2.00$2.00
Payout ratio50%50%
1-year div growth0%5% ✓
5-year div CAGR0%5% ✓
Portfolio after 10y$4.879226400974806e+39M$28.0K ✓
Annual income after 10y$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00 ✓$899.19
Total dividends collected$4.879195005460081e+39M$6.4K ✓
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: CDXI vs NOBL ($10,000, DRIP)

YearCDXI PortfolioCDXI Income/yrNOBL PortfolioNOBL Income/yrGap
1← crossover$200,010,700$200,000,000.00$11,120$420.00+$200.00M → CDXI
2$3,738,731,768,458$3,738,517,757,009.35$12,357$458.31+$3738731.76M → CDXI
3$65,315,062,866,930,490$65,311,062,423,938,240.00$13,721$499.76+$65315062866.92M → CDXI
4$1,066,400,830,062,625,000,000$1,066,330,942,945,357,500,000.00$15,227$544.58+$1066400830062625.00M → CDXI
5$16,272,182,796,453,826,000,000,000$16,271,041,747,565,660,000,000,000.00$16,885$593.02+$16272182796453826560.00M → CDXI
6$232,054,240,113,661,900,000,000,000,000$232,036,828,878,069,680,000,000,000,000.00$18,713$645.34+$2.3205424011366188e+23M → CDXI
7$3,092,799,066,104,688,500,000,000,000,000,000$3,092,550,768,067,767,400,000,000,000,000,000.00$20,724$701.81+$3.0927990661046884e+27M → CDXI
8$38,524,105,697,352,694,000,000,000,000,000,000,000$38,520,796,402,351,967,000,000,000,000,000,000,000.00$22,938$762.73+$3.8524105697352695e+31M → CDXI
9$448,468,826,014,798,700,000,000,000,000,000,000,000,000$448,427,605,221,702,600,000,000,000,000,000,000,000,000.00$25,372$828.41+$4.484688260147987e+35M → CDXI
10$4,879,226,400,974,806,000,000,000,000,000,000,000,000,000,000$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00$28,047$899.19+$4.879226400974806e+39M → CDXI

CDXI vs NOBL: Complete Analysis 2026

CDXI — Stock

Cardax, Inc., a biopharmaceutical company, develops and commercializes dietary supplements for inflammatory health and pharmaceuticals for chronic diseases driven by inflammation and oxidative stress. It offers ZanthoSyn, an inflammatory supplement for health and longevity that provides astaxanthin with enhanced absorption and purity. The company sells ZanthoSyn primarily through e-commerce and wholesale channels. It is also developing CDX-101, an astaxanthin pharmaceutical candidate for cardiovascular inflammation and dyslipidemia, with a target indication of severe hypertriglyceridemia; and CDX-301, a zeaxanthin pharmaceutical candidate for macular degeneration. Cardax, Inc. is based in Honolulu, Hawaii.

Full CDXI Calculator →

NOBL — ETF

NOBL is a dividend-paying stock. Use this calculator to estimate your future dividend income, DRIP compounding returns, and passive income potential from investing in NOBL shares.

Full NOBL Calculator →
📬

Get this CDXI vs NOBL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CDXI vs SCHDCDXI vs JEPICDXI vs OCDXI vs KOCDXI vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.